Stockscreener 앱 받기
8.28
1.78%
-0.15
시간 외 거래:
8.24
-0.04
-0.48%
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa
Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com
Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener
Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Buy” at The Goldman Sachs Group - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects - TipRanks
Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential - Investing.com Nigeria
Amylyx Pharmaceuticals Insiders Sell US$678k Of Stock, Possibly Signalling Caution - simplywall.st
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Amylyx (AMLX) Soars 3.25% on FDA Fast Track Designation - AInvest
Mitsubishi UFJ Financial Group, Inc. Announces Filing of Annual Report on Form 20-F for the Year Ended March 31, 2025 - The Globe and Mail
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Breakthrough for Post-Bariatric Hypoglycemia - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia - TipRanks
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) added to Russell Small Cap Comp Growth Index - MarketScreener
Why Shares In Amylyx Pharmaceuticals Soared This Week - Barchart.com
After myriad failures, a new wave of ALS drugs approaches - Pharma Voice
Amylyx initiated with a Buy at Guggenheim on ‘blockbuster potential’ - TipRanks
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash MarketAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at Citigroup - Defense World
Citi initiates Amylyx stock with buy rating on promising pipeline By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Citi initiates Amylyx stock with buy rating on promising pipeline - Investing.com
Amylyx Pharmaceuticals (AMLX): Citigroup Initiates Coverage with 'Buy' Rating | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at Citi - TipRanks
Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage | AMLX Stock News - GuruFocus
Diabetes Insipidus Market Statistics Expected to Experience - openPR.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
# H.C. Wainwright reiterates Buy rating on AMYLYX stock ahead of trial - Investing.com India
Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
AMX0114 receives FDA fast track status for the treatment of ALS - ALS News Today
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wellington Management Group LLP Purchases New Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Ameriprise Financial Inc. Purchases Shares of 50,428 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting - TipRanks
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
0.64%
0.37%
자본화:
|
볼륨(24시간):